论文部分内容阅读
目的 观察新型乙型肝炎病毒 (HBV)表面抗原中蛋白 (MHBs)核酸疫苗的免疫原性。方法 以新型人体应用载体质粒pSW 3891构建MHBs核酸疫苗 (pSW3891 /MHBs/adr) ,对照组和实验组Balb/c小鼠分别基因枪法免疫对照载体质粒 (pSW 3891 )和MHBs核酸疫苗 ,采用酶联免疫吸附试验检测抗HBs ,LDH释放测定法检测小鼠特异性细胞毒T淋巴细胞 (CTL)杀伤活性。结果 MHBs核酸疫苗可在体外高效表达 ,免疫小鼠后可产生高滴度抗HBs,血清阳性终点滴度达 1∶972 0 0 ,小鼠脾细胞HBs特异性细胞毒性T淋巴细胞 (CTL)杀伤活性达 78 81 %。结论 新型MHBs核酸疫苗在Balb/c小鼠实验中表现出良好的体液和细胞免疫原性
Objective To observe the immunogenicity of novel hepatitis B virus (HBV) surface antigen protein (MHB) nucleic acid vaccine. Methods The recombinant plasmid pSW 3891 (pSW3891 / MHBs / adr) was constructed and the control and experimental Balb / c mice were immunized with plasmid vector pSW 3891 and DNA vaccine of MHBs respectively. Immunosorbent assay detected anti-HBs, LDH release assay specific cytotoxic T lymphocytes (CTL) killing activity. Results MHBs DNA vaccine could be efficiently expressed in vitro. High titer of anti-HBs could be produced in mice after immunization. The final serum titer reached 1: 972 000, and the cytotoxic T lymphocytes (CTLs) of mouse spleen cells were killed Activity up to 7881%. Conclusion The novel MHBs nucleic acid vaccine showed good humoral and cellular immunogenicity in Balb / c mice